Stocktwits on MSN

Disc Medicine, Sanofi, Eli Lilly shares slip on reports of FDA increasing review time for drugs granted priority review vouchers

FDA is slated to decide on Disc Medicine's Bitopertin by February. ・Approval for Lilly’s obesity pill is expected by April 10 ...

Disc Medicine and Sanofi reportedly face delays for FDA national priority review vouchers

Two drugs developed by Disc Medicine (IRON) and Sanofi (SNY) are facing delays in their review timelines due to safety and ...

Disc Medicine (IRON) Valuation Check As Bitopertin Wins Priority FDA Review And Commercial Plans Advance

Disc Medicine (IRON) has drawn fresh attention after securing priority FDA review for bitopertin and outlining ...

Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026

Bitopertin was awarded the Commissioner’s National Priority Review Voucher (CNPV) and NDA is currently under FDA reviewUpdated data from the ...
Seeking Alpha

Disc Medicine: NDA Submission And CNPV For Bitopertin Further Boost Shareholder Value

The last time I spoke about Disc Medicine (IRON) it was with respect to a Seeking Alpha article entitled "Disc Medicine: Rare Disease Biotech With Enormous Potential". With respect to this article I ...